TWO TOWER PLACE, SOUTH SAN FRANCISCO, CA
Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases
Reports First Quarter 2026 Financial Results and Recent Highlights
Annual Report to Security Holders
Assembly Biosciences Announces 2026 Corporate Bonus Plan Approval
Reports Year-End 2025 Financial Results and Recent Highlights
Assembly Biosciences Shows Positive Phase 1b Results for ABI-1179 and ABI-5366 in Genital Herpes
Financial Results, Press Release
Announces Pricing of $175 Million in Equity Financings
Q1
FY 2025
Q3
Q2
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Additional Proxy Materials
Definitive Proxy Statement
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Correspondence
Submission Upload